Search research articles
Contact Us
Filters
Showing results (681-690 of 755) with videos related to
Page
of 76
Sort By:
Arthritis and Rheumatism
|
September 30, 2008
The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial
Allen D Sawitzke, Helen Shi, Martha F Finco, et al.
The Journal of Rheumatology
|
January 17, 2019
Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative
Sabrina M Nielsen, Peter Tugwell, Maarten P T de Wit, et al.
Expert Review of Clinical Immunology
|
June 5, 2026
Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium
Ivan Foeldvari, Kathryn S Torok, Jens Klotsche, et al.
Clinical Rheumatology
|
April 27, 2018
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study
Dimitrios A Pappas, Fredrik Nyberg, Joel M Kremer, et al.
Annals of the Rheumatic Diseases
|
January 17, 2009
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
O Kowal-Bielecka, R Landewé, J Avouac, et al.
Annals of the Rheumatic Diseases
|
October 30, 2008
European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research
J Avouac, O Kowal-Bielecka, R Landewe, et al.
Annals of the Rheumatic Diseases
|
October 15, 2020
Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group
Sabrina Mai Nielsen, Marianne Uggen Rasmussen, Maarten Boers, et al.
Annals of the Rheumatic Diseases
|
October 29, 2000
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)
D E Furst, F C Breedveld, G R Burmester, et al.
Arthritis and Rheumatism
|
November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial
Paul J DeMarco, Michael H Weisman, James R Seibold, et al.
Arthritis and Rheumatism
|
February 5, 2005
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study
Dinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Page
of 76
Search research articles
Search
Showing results (681-690 of 755) with videos related to
Sort By:
Page
of 76
Arthritis and Rheumatism
|
September 30, 2008
The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial
Allen D Sawitzke, Helen Shi, Martha F Finco, et al.
The Journal of Rheumatology
|
January 17, 2019
Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative
Sabrina M Nielsen, Peter Tugwell, Maarten P T de Wit, et al.
Expert Review of Clinical Immunology
|
June 5, 2026
Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium
Ivan Foeldvari, Kathryn S Torok, Jens Klotsche, et al.
Clinical Rheumatology
|
April 27, 2018
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study
Dimitrios A Pappas, Fredrik Nyberg, Joel M Kremer, et al.
Annals of the Rheumatic Diseases
|
January 17, 2009
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
O Kowal-Bielecka, R Landewé, J Avouac, et al.
Annals of the Rheumatic Diseases
|
October 30, 2008
European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research
J Avouac, O Kowal-Bielecka, R Landewe, et al.
Annals of the Rheumatic Diseases
|
October 15, 2020
Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group
Sabrina Mai Nielsen, Marianne Uggen Rasmussen, Maarten Boers, et al.
Annals of the Rheumatic Diseases
|
October 29, 2000
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)
D E Furst, F C Breedveld, G R Burmester, et al.
Arthritis and Rheumatism
|
November 13, 2002
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial
Paul J DeMarco, Michael H Weisman, James R Seibold, et al.
Arthritis and Rheumatism
|
February 5, 2005
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study
Dinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Page
of 76